Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,404,750.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. This represents a 10.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Trading Down 1.9 %

NASDAQ:JANX opened at $54.10 on Friday. The company has a 50-day moving average price of $54.43 and a 200-day moving average price of $47.46. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -46.24 and a beta of 3.29. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. Equities analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently made changes to their positions in JANX. Plato Investment Management Ltd lifted its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares in the last quarter. Amalgamated Bank lifted its position in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the period. Virtu Financial LLC boosted its stake in Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after acquiring an additional 2,419 shares in the last quarter. Finally, Zacks Investment Management grew its holdings in Janux Therapeutics by 8.7% in the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock worth $1,914,000 after purchasing an additional 3,360 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. BTIG Research lifted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. HC Wainwright raised their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. Finally, Leerink Partners increased their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.